Novo Nordisk shares rise before heart risk data

Novo Nordisk shares increased on Monday as the company announced it will present new data on semaglutide, the active ingredient in Ozempic and Wegovy, at an upcoming medical conference. This data will focus on reducing heart risks. The announcement follows disappointing results from a recent trial of another weight-loss drug, CagriSema, which showed lower-than-expected weight loss. Shares rose over 3% during intraday trading, recovering some losses from last week. Despite the recent gains, Novo Nordisk shares are down about 7% this year and have lost 40% of their value over the past 12 months.